Biolevate’s raises €6M to helps medical writers keep up with the pace of new drugs

Advancements in Medical Writing Efficiency

The development of new drugs requires extensive documentation, a process that is traditionally labor-intensive and lacks modern software solutions. BioLevitt is addressing this challenge with a platform that leverages natural language processing (NLP) and visual document reading to enhance the efficiency of medical writers. Co-founders Joel Belafa and Nathan Chen highlighted their shared frustrations with the slow pace of research, development, and market access in the biotech industry, which adversely affects patient outcomes and the economy. Their platform, ELISE, acts as an AI assistant, optimizing the creation and management of essential research and compliance documents, thus significantly alleviating the administrative burdens faced by pharmaceutical companies.